

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A Tetrahedron Publication for the Rapid Dissemination of Preliminary Communications on all
Aspects of Bioorganic Chemistry, Medicinal Chemistry, Bioinorganic Chemistry
and Related Disciplines

Editor-in-Chief

Professor D. L. Boger

European Regional Editor

Professor S. Neidle

Japanese Regional Editor

Professor M. Shibasaki




ELSEVIER

Amsterdam • Boston • London • New York • Oxford • Paris • Philadelphia • San Diego • St. Louis

Printed in the United States of America



0960-894X(20100415)20:8;1-5



972

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Editor-in-Chief: Professor D. L. BOGER

Department of Chemistry, BCC 483A, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Facsimile: (1) 619-699-6700

European Regional Editor: Professor S. Neidle, Department of Pharmaceutical & Biological Chemistry, The School of Pharmacy, University of London, 29/39 Brunswick Square, London WC1N 1AX, UK.
Facsimile: 020 7753 5970

Japanese Regional Editor: Professor M. Shibasaki, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Facsimile: (81) 3 5684 5206

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: Professor H. Waldmann

Editor Emeritus: Professor H. H. Wasserman

Professor D. L. Boger, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. G. Davies, Dyson Perrins Laboratory, Department of Chemistry, University of Oxford, Oxford OX1 3QY, UK

Professor B. Ganem, Department of Chemistry & Chemical Biology, Baker Laboratory, Cornell University, Ithaca, NY 14853-1301, USA

Professor L. Ghose, l'Institut Européen de Chimie et de Biologie (IECB), 33607 Pessac Cedex, France

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 354 Fenglin Road, Shanghai 200032, China

Professor Y. Hashimoto, Institute of Molecular & Cellular Biosciences, The University of Tokyo, III-Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan

Professor T. Hayashi, Department of Chemistry, Faculty of Science, Kyoto University, Kyoto 606, Japan

Professor K. D. Janda, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor S. F. Martin, Department of Chemistry & Biochemistry, University of Texas, Austin, TX 78712, USA

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor S. Neidle, The School of Pharmacy, Department of Pharmaceutical & Biological Chemistry, University of London, London WC1N 1AX, UK

Professor M. Shibasaki, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Professor R. J. K. Taylor, Department of Chemistry, University of York, Heslington, York YO10 5DD, UK
(Associate Editors, Dr P. A. O'Brien and Dr D. K. Smith)

Professor K. Tomioka, Graduate School of Pharmaceutical Sciences, Department of Synthetic Medicinal Chemistry, Kyoto University, Kyoto 606-8501, Japan

Professor E. J. Thomas, Department of Chemistry, University of Manchester, Brunswick Street, Manchester M13 9PL, UK
(Associate Editor, Professor J. A. Joule)

Professor H. Waldmann, Max-Planck-Inst. für Molekular Physiologie, Department of Chemistry, Otto-Hahn-Strasse 11, 44227 Dortmund, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520-8107, USA

Professor R. M. Williams, Department of Chemistry, Colorado State University, Fort Collins, CO 80523

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Professor J. Wood, Department of Chemistry, Colorado State University, Fort Collins, CO 80523-1872

Professor Y. Yamamoto, Department of Chemistry, Graduate School of Science, Tohoku University, Sendai 980-8578, Japan
(Associate Editor, Professor M. Hirama)

Professor S. Z. Zard, Laboratoire de Synthèse Organique, Ecole Polytechnique, F-91128 Palaiseau Cedex, France
(Associate Editor, Dr B. Sire)

BOARD OF CONSULTING EDITORS

P. S. Anderson, Wilmington, DE
K.-H. Altmann, Zürich
P. G. Baraldi, Ferrara
C. F. Barbas, III, La Jolla, CA
J. K. Barton, Pasadena, CA
C. R. Bertozzi, Berkeley, CA
R. C. Breslow, New York, NY
T. C. Bruice, Santa Barbara, CA
A. R. Chamberlin, Irvine, CA
E. J. Corey, Cambridge, MA
B. Cravatt, La Jolla, CA
S. J. Danishefsky, New York, NY
P. B. Dervan, Pasadena, CA
A. Eschenmoser, Zürich
J.-M. Fang, Taipei

A. R. Fersht, Cambridge
D. M. Floyd, Princeton, NJ
G. I. Georg, Minneapolis, MN
A. Giannis, Leipzig
B. Giese, Basel
P. Gemeiner, Erlangen
H. B. Gray, Pasadena, CA
G. L. Grunewald, Lawrence, KS
P. Herrling, Basel
D. Hilvert, Zürich
L. C. Hsieh-Wilson, Pasadena, CA
W. L. Jorgensen, New Haven, CT
A. R. Katritzky, Gainesville, FL
J. A. Katzenellenbogen, Urbana, IL
J. Kelly, La Jolla, CA

P. Krosgaard-Larsen, Copenhagen
R. A. Lerner, La Jolla, CA
H. Liu, Austin, TX
A. McKillop, Northumberland
R. Metternich, Berlin
S. Mignani, Vitry-sur-Seine
L. A. Mitscher, Lawrence, KS
K. C. Nicolaou, La Jolla, CA
H. L. Pearce, Indianapolis, IN
C. D. Poulter, Salt Lake City, UT
J. Rebek, Jr., La Jolla, CA
B. Samuelsson, Stockholm
J. Saunders, San Diego, CA
S. L. Schreiber, Cambridge, MA
P. G. Schultz, La Jolla, CA

P. Seeberger, Zürich
O. Seitz, Berlin
K. Shokat, San Francisco, CA
R. Silverman, Evanston, IL
J. Stubbe, Cambridge, MA
C. T. Supuran, Firenze
G. L. Verdine, Cambridge, MA
S. Walker, Cambridge, MA
C. T. Walsh, Boston, MA
P. A. Wender, Stanford, CA
G. Whitesides, Cambridge, MA
R. V. Wolfenden, Chapel Hill, NC

Publication information: *Bioorganic & Medicinal Chemistry Letters* (ISSN 0960-894X) is published semimonthly by Elsevier (Radarweg 29, 1043 NX Amsterdam, the Netherlands). Further information on this journal is available from the Publisher or from the Elsevier Customer Service Department nearest you or from this journal's website (<http://www.elsevier.com/locate/bmcl>). Information on other Elsevier products is available through Elsevier's website (<http://www.elsevier.com>). Periodicals Postage Paid at Rahway, NJ, and at additional mailing offices. USA POSTMASTER: Send change of address to *Bioorganic & Medicinal Chemistry Letters*, Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA.

Orders, claims, and journal inquiries: Please contact the Elsevier Customer Service Department nearest you. **St. Louis:** Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (877) 8397126 [toll free within the USA]; (+1) (314) 4478878 [outside the USA]; fax: (+1) (314) 4478077; e-mail: JournalCustomerService-usa@elsevier.com. **Oxford:** Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCustomerServiceEMEA@elsevier.com. **Tokyo:** Elsevier Customer Service Department, 4F Higashi-Azabu, 1-Chome Bldg., 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com. **Singapore:** Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustomerServiceAPAC@elsevier.com.

Author inquiries: For inquiries relating to the submission of articles (including electronic submission where available), please visit this journal's homepage at <http://www.elsevier.com/locate/bmcl>. You can track accepted articles at <http://www.elsevier.com/trackarticle> and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions, and more. For detailed instructions on the preparation of electronic artwork, please visit <http://www.elsevier.com/artworkinstructions>. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.

For a full and complete Guide for Authors, please go to: <http://www.elsevier.com/locate/bmcl>.

Advertising information: Advertising orders and enquiries can be sent to: Janine Castle, Elsevier Ltd., The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) 1865 843 844; fax: (+44) 1865 843 973; e-mail: j.castle@elsevier.com.

Funding body agreements and policies: Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit <http://www.elsevier.com/fundingbodies>.

Printed in the United States of America

© The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)

© 2010 Elsevier Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by Elsevier Ltd., and the following terms and conditions apply to their use:

Photocopying: Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

For information on how to seek permission visit www.elsevier.com/permissions or call: (+44) 1865 843830 (UK) / (+1) 215 239 3804 (USA).

Derivative works: Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions).

Electronic storage or usage: Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article (please consult www.elsevier.com/permissions).

Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.


Notice: No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee.



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl


Bioorganic & Medicinal Chemistry Letters Volume 20, Issue 8, 2010


Contents

ARTICLES

Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor

pp 2408–2411

Timothy P. Heffron*, Megan Berry, Georgette Castanedo, Christine Chang, Irina Chuckowree, Jennafer Dotson, Adrian Folkes, Janet Gunzner, John D. Lesnick, Cristina Lewis, Simon Mathieu, Jim Nonomiya, Alan Olivero, Jodie Pang, David Peterson, Laurent Salphati, Deepak Sampath, Steve Sideris, Daniel P. Sutherlin, Vickie Tsui, Nan Chi Wan, Shumei Wang, Susan Wong, Bing-yan Zhu




Efforts to identify potent small molecule inhibitors of PI3 kinase and mTOR led to the evaluation of tetrasubstituted thienopyrimidines. These molecules generally have reduced in vivo clearance relative to the trisubstituted thienopyrimidines culminating in the identification of **GNE-477 (8)**.

Homoisoflavonoid derivatives from the roots of *Ophiopogon japonicus* and their in vitro anti-inflammation activity

pp 2412–2416

Tran Manh Hung, Cao Van Thu, Nguyen Tien Dat, Sung-Woo Ryoo, Jeong Hyung Lee, Jin Cheol Kim, Minkyun Na, Hyun-Ju Jung, KiHwan Bae*, Byung Sun Min*




Three new homoisoflavonoids (**1–3**) were isolated from the roots of *Ophiopogon japonicus* (Liliaceae) and investigated by their effects on the release of the inflammatory chemokine eotaxin, stimulated by IL-4 and the combination of IL-4 and TNF- α in BEAS-2B cells.

Antioxidant and antiproliferative activities of hydroxyl-substituted Schiff bases

pp 2417–2420

Li-Xia Cheng, Jiang-Jiang Tang, Hui Luo, Xiao-Ling Jin, Fang Dai, Jie Yang, Yi-Ping Qian, Xiu-Zhuang Li, Bo Zhou*




Eight hydroxyl-substituted Schiff bases were synthesized and bio-evaluated for their antioxidant and antiproliferative activities. Structure–activity relationship analysis indicates that o-diphenolic groups and 4-hydroxyl group attached to the aromatic B ring contribute critically to the activities.



Synthesis and SOD activity of manganese complexes of substituted pyridino pentaaza macrocycles that contain axial auxiliary

pp 2421–2424

Hakyong Lee, Wonchoul Park, Dongyeol Lim*




The synthesis and SOD-like activity of new manganese(II) complex of substituted pyridino pentaaza macrocyclic ligands are reported.



γ -Lactams as glycinamide replacements in cyclohexane-based CC chemokine receptor 2 (CCR2) antagonists

pp 2425–2430

Robert J. Cherney*, Ruowei Mo, Dayton T. Meyer, Matthew E. Voss, Michael G. Yang, Joseph B. Santella III, John V. Duncia, Yvonne C. Lo, Gengjie Yang, Persymphonie B. Miller, Peggy A. Scherle, Qihong Zhao, Sandhya Mandlekar, Mary Ellen Cvijic, Joel C. Barrish, Carl P. Decicco, Percy H. Carter




We describe the design, synthesis, and evaluation, of γ -lactams as glycinamide replacements within a series of di- and trisubstituted cyclohexane CCR2 antagonists.

B-Raf kinase inhibitors: Hit enrichment through scaffold hopping

pp 2431–2434

Ariamala Gopalsamy*, Mengxiao Shi, Yongbo Hu, Frederick Lee, Larry Feldberg, Eileen Frommer, Steven Kim, Karen Collins, Donald Wojciechowicz, Robert Mallon




Scaffold hopping strategy was employed to replace the HTS hit scaffold pyrazolo[1,5-a]pyrimidine. This strategy led to the identification of additional lead compound **11b** with enhanced enzyme and cellular potency, while maintaining good selectivity over a number of kinases.

Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: Part 2

pp 2435–2437

Akira Nakao*, Nobuyuki Ohkawa, Takayoshi Nagasaki, Takashi Kagari, Hiromi Doi, Takaichi Shimoizato, Shigeru Ushiyama, Kazumasa Aoki




The synthesis of the proinflammatory cytokine production inhibitor **3o** (TNF α IC_{50} = 0.44 μ M) and **3j** (TNF α ID_{50} = 1.42 mg/kg) are reported.



Spectacular modification of Gambogic acid on microwave irradiation in methanol: Isolation and structure identification of two products with potent anti-tumor activity

pp 2438–2442

Xiaojian Wang, Na Lu, Qian Yang, Qinsheng Dai, Lei Tao, Xiaoke Guo, Qinglong Guo*, Qidong You*




Treatment of gambogic acid with methanol in acidic condition under microwave irradiation led to the formation of two new products bearing spectacular A ring systems with promising anti-tumor effect.



Synthesis and evaluation of alkenyl indazoles as selective Aurora kinase inhibitors

pp 2443–2447

Stéphanie Blanchard*, Anthony D. William, Angeline C.-H. Lee, Anders Poulsen, Ee Ling Teo, Weiping Deng, Noah Tu, Evelyn Tan, Kay Lin Goh, Wai Chung Ong, Chee Pang Ng, Kee Chuan Goh, Zahid Bonday, Eric T. Sun




A series of alkenyl indazole derivatives were prepared and evaluated as selective Aurora inhibitors.

Towards biomarker-dependent individualized chemotherapy: Exploring cell-specific differences in oxaliplatin–DNA adduct distribution using accelerator mass spectrometry

pp 2448–2451


Sang Soo Hah*, Paul T. Henderson, Kenneth W. Turteltaub



Imidazo[2,1-b]thiazoles: Multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family of receptor tyrosine kinases

pp 2452–2455

Steve D. Fidanze*, Scott A. Erickson, Gary T. Wang, Robert Mantei, Richard F. Clark, Bryan K. Sorensen, Nwe Y. Bamaung, Peter Kovar, Eric F. Johnson, Kerren K. Swinger, Kent D. Stewart, Qian Zhang, Lora A. Tucker, William N. Pappano, Julie L. Wilsbacher, Jieyi Wang, George S. Sheppard, Randy L. Bell, Steven K. Davidsen, Robert D. Hubbard




The design and enzyme activities of a novel class of imidazo[2,1-b]thiazoles is presented.



Antimicrobial selaginellin derivatives from *Selaginella pulvinata*


pp 2456–2460

Yuan Cao, Ji-Jun Chen, Ning-Hua Tan, Lukas Oberer, Trixie Wagner, Yong-Ping Wu, Guang-Zhi Zeng, He Yan, Qiang Wang*

Selaginellin derivatives from *Selaginella pulvinata* with good antimicrobial activity.**Design, synthesis, and antibiofilm activity of 2-arylimino-3-aryl-thiazolidine-4-ones**


pp 2461–2464

Bin Pan, Ren-Zheng Huang, Shi-Qing Han*, Di Qu, Ming-Li Zhu, Ping Wei, Han-Jie Ying

The minimal inhibitory concentration (MIC), minimal bactericidal concentration (MBC) and antibiofilm concentration assay of **1x** were 6.25 μ M, 25 μ M and 6.25 μ M against *Staphylococcus epidermidis*, respectively.**The development and validation of a novel virtual screening cascade protocol to identify potential serotonin 5-HT₇R antagonists**


pp 2465–2468

Rafał Kurczab, Mateusz Nowak, Zdzisław Chilmonczyk, Ingebrigt Sylte, Andrzej J. Bojarski*

**Rational design of a pirinixic acid derivative that acts as subtype-selective PPAR γ modulator**

pp 2469–2473


Theresa M. Thieme, Ramona Steri, Ewgenij Proschak, Alexander Paulke, Gisbert Schneider, Manfred Schubert-Zsilavecz*

A series of pirinixic acid derivatives were synthesized and evaluated as subtype-selective peroxisome proliferator-activated receptor (PPAR γ) agonists and modulator by in vitro transactivation of human PPARs.

A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties


pp 2474–2477

T. K. Sasikumar*, Li Qiang, Duane A. Burnett, William J. Greenlee, Cheng Li, Mariagrazia Grilli, Rosalia Bertorelli, Gianluca Lozza, Angelo Reggiani

**A novel D-glucose derivative radiolabeled with technetium-99m: Synthesis, biodistribution studies and scintigraphic images in an experimental model of Ehrlich tumor**

pp 2478–2480

André Luís Branco de Barros, Valbert Nascimento Cardoso, Luciene das Graças Mota, Elaine Amaral Leite, Mônica Cristina de Oliveira, Ricardo José Alves*




A D-glucose analogue was synthesized; its biodistribution studies and scintigraphic images were performed.

Praziquantel analogs with activity against juvenile *Schistosoma mansoni*

pp 2481–2484


Yuxiang Dong, Jacques Chollet, Mireille Vargas, Nuha R. Mansour, Quentin Bickle, Yazan Alnouti, Jiangeng Huang, Jennifer Keiser, Jonathan L. Vennerstrom*

**Eastern extension of azoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase; cyano group alternatives**

pp 2485–2488


Cheryl S. Leung, Jacob G. Zeevaert, Robert A. Domaal, Mariela Bollini, Vinay V. Thakur, Krasimir A. Spasov, Karen S. Anderson*, William L. Jorgensen*

Synthesis, assaying, and computational results are reported for new anti-HIV agents that exhibit high potency and low cytotoxicity. Extension into an eastern channel in the HIV-1 reverse transcriptase binding site is investigated.




Synthesis and characterization of a Eu-DTPA-PEGO-MSH(4) derivative for evaluation of binding of multivalent molecules to melanocortin receptors pp 2489–2492

Liping Xu, Josef Vagner, Ramesh Alleti, Venkataramanarao Rao, Bhumasamudram Jagadish, David L. Morse, Victor J. Hruby, Robert J. Gillies, Eugene A. Mash*




Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel pp 2493–2496

Douglas C. Beshore*, Nigel J. Liverton, Charles J. McIntyre, Christopher F. Claiborne, Brian Libby, J. Christopher Culberson, Joseph J. Salata, Christopher P. Regan, Joseph J. Lynch, Laszlo Kiss, Robert H. Spencer, Stephanie A. Kane, Rebecca B. White, Suzie Yeh, George D. Hartman, Christopher J. Dinsmore



Identification of very potent inhibitor of human aminopeptidase N (CD13) pp 2497–2499


Renata Grzywa, Józef Oleksyszyn, Guy S. Salvesen, Marcin Drąg*



New potent human aminopeptidase N (CD13) inhibitor (IC₅₀ = 60 nM) is reported.

Natural products-based insecticidal agents 5. Design, semisynthesis and insecticidal activity of novel 4'-substituted benzenesulfonate derivatives of 4-deoxypodophyllotoxin against *Mythimna separata* Walker in vivo pp 2500–2502


Hui Xu*, Juan-Juan Wang




Some 4'-substituted benzenesulfonates of 4-deoxypodophyllotoxin exhibited the potent insecticidal activity.

N-Aryltriazole ribonucleosides with potent antiproliferative activity against drug-resistant pancreatic cancer pp 2503–2507


Yang Liu, Yi Xia, Yuting Fan, Alain Maggiani, Palma Rocchi, Fanqi Qu, Juan L. Iovanna, Ling Peng*

**Carbonic anhydrase inhibitors. The β -carbonic anhydrases from the fungal pathogens *Cryptococcus neoformans* and *Candida albicans* are strongly inhibited by substituted-phenyl-1H-indole-5-sulfonamides** pp 2508–2511

Özlen Güzel, Alfonso Maresca, Rebecca A. Hall, Andrea Scozzafava, Antonio Mastrolorenzo, Fritz A. Mühlischlegel, Claudiu T. Supuran*

 $K_i = 640 \text{ nM}$ (hCA I); $K_i = 38.8 \text{ nM}$ (hCA II); $K_i = 8.0 \text{ nM}$ (Can2); $K_i = 45 \text{ nM}$ (CaNce103).**Synthesis and biological evaluation of piperazinyl heterocyclic antagonists of the gonadotropin releasing hormone (GnRH) receptor** pp 2512–2515


Matthew D. Vera, Joseph T. Lundquist IV, Murty V. Chengalvala, Joshua E. Cottom, Irene B. Feingold, Lloyd M. Garrick, Daniel M. Green, Diane B. Hauze, Charles W. Mann, John F. Mehlmann, John F. Rogers, Linda Shanno, Jay E. Wrobel, Jeffrey C. Pelletier*

 $X = \text{N(H)}, \text{O}, \text{S}; Y = \text{C}, \text{N}; Z = \text{N(H)}, \text{O}, \text{S}$

A series of bicycloheterocyclic replacements for the previously described benzimidazole template were prepared and tested for GnRH activity.


**Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists** pp 2516–2519

Sue Cramp*, Hazel J. Dyke, Christopher Higgs, David E. Clark, Matthew Gill, Pascal Savy, Neil Jennings, Steve Price, Peter M. Lockey, Dennis Norman, Soraya Porres, Francis Wilson, Alison Jones, Nigel Ramsden, Raffaella Mangano, Dan Leggate, Marie Andersson, Richard Hale




The hit-to-lead exploration of a series of novel, potent and selective series of histamine H4 receptor inverse agonists originating from a virtual screening approach is described.

Ghotas Evindar*, Sylvie G. Bernier, Elisabeth Doyle, Malcolm J. Kavarana, Alexander L. Satz, Jeanine Lorusso, Heather S. Blanchette, Ashis K. Saha, Gerhard Hannig, Barry A. Morgan, William F. Westlin



Synthesis, cytotoxic activity and structure–activity relationships of hedychenone analogues

P. Prabhakar Reddy, Aditya G. Lavekar, K. Suresh Babu, R. Ranga Rao, J. Shashidhar, G. Shashikiran, J. Madhusudana Rao*




A series of analogues have been synthesized by modification of the furanoid ring, double bond and the vinylic methyl functionality of this natural product lead. All the compounds were tested for their in vitro cytotoxic activity against human cancer cell lines.




[¹¹C]Dimebon, radiosynthesis and lipophilicity of a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease pp 2529–2532

Mingzhang Gao, Min Wang, Gary D. Hutchins, Qi-Huang Zheng*

Radiosynthesis and lipophilicity of [^{11}C]Dimebon, a new potential PET agent for imaging of Alzheimer's disease and Huntington's disease, are first reported.

Heterocyclic fused pyridone carboxylic acid M₁ positive allosteric modulators pp 2533–2537


Scott D. Kuduk*, Christina N. Di Marco, Ronald K. Chang, William J. Ray, Lei Ma, Marion Wittmann, Matthew A. Seager, Kenneth A. Koepfinger, Charles D. Thompson, George D. Hartman, Mark T. Bilodeau



The phenyl ring in a series of quinolone carboxylic acid M₁ positive allosteric modulators was replaced with a variety of heterocycles in order to reduce protein plasma binding and enhance CNS exposure.

Hydroxy cycloalkyl fused pyridone carboxylic acid M₁ positive allosteric modulators pp 2538–2541


Scott D. Kuduk*, Robert M. DiPardo, Douglas C. Beshore, William J. Ray, Lei Ma, Marion Wittmann, Matthew A. Seager, Kenneth A. Koeplinger, Charles D. Thompson, George D. Hartman, Mark T. Bilodeau



Incorporation of hydroxycycloalkyl fused pyridone carboxylic acids in lieu of quinolone carboxylic acids enhance free fraction without increased susceptibility to P-glycoprotein transport.

Benzyl prolinates as novel selective KCC2 blockers pp 2542–2545

Cécile Pégurier*, Nathalie Bosman, Philippe Collart, Marie-Laure Delporte, Karine Leclercq, Sébastien Lengelé, Ananda Kumar Kanduluru, Stéphane Meunier, Nathalie Pacico, Lakshmana Rao Vadali, Alain Wagner, Christian Wolff, Laurent Provins




13

The benzyl proline **13** has been identified as a potent KCC2 blocker with selectivity versus NKCC1 and favorable ADME properties. It was evaluated in an in vivo model of epilepsy, the audiogenic mouse seizure test.

Chemopreventive activities of etodolac and oxyphenbutazone against mouse skin carcinogenesis pp 2546–2548

Govind J. Kapadia*, Magnus A. Azuine, Yuuko Shigeta, Nobutaka Suzuki, Harukuni Tokuda




Etodolac

Oxyphenbutazone

Inhibition of mouse skin cancer by non-steroidal anti-inflammatory drugs, etodolac and oxyphenbutazone is reported.

Curcumin derivatives inhibit testicular 17 β -hydroxysteroid dehydrogenase 3 pp 2549–2551

Guo-Xin Hu, Guang Liang, Yanhui Chu, Xiaokun Li, Qing-Quang Lian*, Han Lin, Yi He, Yadong Huang, Dianne O. Hardy, Ren-Shan Ge*




Curcumin

Discovery of a new series of Aurora inhibitors through truncation of GSK1070916

pp 2552–2555

Jesus R. Medina*, Seth W. Grant, Jeffrey M. Axten, William H. Miller, Carla A. Donatelli, Mary Ann Hardwicke, Catherine A. Oleykowski, Qiaoyin Liao, Ramona Plant, Hong Xiang




The SAR results from this investigation will be presented with an emphasis on the impact structural changes have on the cellular phenotype.

Amide-based inhibitors of p38 α MAP kinase. Part 1: Discovery of novel *N*-pyridyl amide lead molecules

pp 2556–2559

Gregory R. Luedtke, Kurt Schinzel, Xuefei Tan*, Richland W. Tester, Imad Nashashibi, Yong-jin Xu, Sundeeep Dugar, Daniel E. Levy*, Joon Jung




A novel series of *N*-pyridyl amide p38 α kinase inhibitors is described. The proposed binding modes of the initial hits were evaluated against SAR findings to provide rationale for further development of this structural class.

Amide-based inhibitors of p38 α MAP kinase. Part 2: Design, synthesis and SAR of potent *N*-pyrimidyl amides

pp 2560–2563

Richland Tester, Xuefei Tan*, Gregory R. Luedtke, Imad Nashashibi, Kurt Schinzel, Weiling Liang, Joon Jung, Sundeeep Dugar, Albert Licican, Jocelyn Tabora, Daniel E. Levy*, Steven Do




Identification and optimization of a new class of *N*-pyrimidyl amide based p38 α MAP kinase inhibitors is described. The lead structure was derived from a previously reported class of pyridine-based amides. p38 α activity (enzymatic/cellular) and CYP3A4 data for the new series are presented.

The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands

pp 2564–2565

Lidiya Stavitskaya, Michael J. Seminerio, Marilyn M. Matthews-Tsourounis, Rae R. Matsumoto, Andrew Coop*





- 1 R = 4-pyridyl, n = 1
- 2 R = 4-pyridyl, n = 2
- 3 R = 3-pyridyl, n = 1
- 4 R = 3-pyridyl, n = 2
- 5* R = 2-pyridyl, n = 1
- 6* R = 2-pyridyl, n = 2

NGF-potentiating vibansane-type diterpenoids from *Viburnum sieboldii*


pp 2566–2571

Miwa Kubo, Yoshiko Kishimoto, Kenichi Harada, Hideaki Hioki, Yoshiyasu Fukuyama*

**Identification of potent, highly constrained CGRP receptor antagonists**


pp 2572–2576

Craig A. Stump*, Ian M. Bell, Rodney A. Bednar, John F. Fay, Steven N. Gallicchio, James C. Hershey, Richard Jelley, Constantine Kreatsoulas, Eric L. Moore, Scott D. Mosser, Amy G. Quigley, Shane A. Roller, Christopher A. Salvatore, Steven S. Sharik, Cory R. Theberge, C. Blair Zartman, Stefanie A. Kane, Samuel L. Graham, Harold G. Selnick, Joseph P. Vacca, Theresa M. Williams

**2,5-Disubstituted pyridines as potent GPR119 agonists**

pp 2577–2581

Yulin Wu*, Judith D. Kuntz, Andrew J. Carpenter*, Jing Fang, Howard R. Sauls, Daniel J. Gomez, Carina Ammala, Yun Xu, Shane Hart, Sarva Tadepalli




A series of 2-piperazinyl-5-alkoxy-pyridines (**3**) were synthesized and screened against human GPR119 receptor. Through SAR analysis, compounds containing 2-alkylsulfonylpiperazinyl-5-alkoxy-pyridines were discovered and found to be potent agonists of the human GPR119 receptor.

Synthesis of substituted *N*-[3-(3-methoxyphenyl)propyl] amides as highly potent MT₂-selective melatonin ligands

pp 2582–2585

Yueqing Hu, Maurice K. C. Ho, King H. Chan, David C. New, Yung H. Wong*




A benzyloxyl substituent incorporated at C6 position of the 3-methoxyphenyl ring dramatically enhanced the melatonin MT₂-binding affinity.



Novel benzofuran-3-one indole inhibitors of PI3 kinase- α and the mammalian target of rapamycin: Hit to lead studies

pp 2586–2590


Matthew G. Bursavich, Natasja Brooijmans, Lawrence Feldberg, Irwin Hollander, Stephen Kim, Sabrina Lombardi, Kaapjoo Park, Robert Mallon, Adam M. Gilbert*



Design and synthesis of tricyclic sulfones as γ -secretase inhibitors with greatly reduced Notch toxicity

pp 2591–2596


Ruo Xu*, David Cole, Ted Asberom, Tom Bara, Chad Bennett, Duane A. Burnett, John Clader, Martin Domalski, William Greenlee, Lynn Hyde, Hubert Josien, Hongmei Li, Mark McBriar, Brian McKittrick, Andrew T. McPhail, Dmitri Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamar Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Lili Zhang, Zhiqiang Zhao



Substituted hydrazinecarbothioamide as potent antitubercular agents: Synthesis and quantitative structure–activity relationship (QSAR)

pp 2597–2600

Supriya Singh, Pintu K. Mandal, Nagendra Singh, Anup K. Misra, Shubhra Singh, Vinita Chaturvedi, Sudhir Sinha, Anil K. Saxena*




A series of novel substituted hydrazinecarbothioamides was synthesized and evaluated for anti-TB activity. Three most active compounds viz. **1**, **6** and **12** were found to exhibit minimum inhibitory concentration (MIC) of 0.4 μ g/mL whereas four compounds viz. **3**, **5**, **10** and **11** showed comparatively lesser activity with MIC value of 0.8 μ g/mL against *Mycobacterium tuberculosis* strain. A highly significant QSAR equation explaining 81.8% variance is described.

(–)-Carbodine: Enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu)

pp 2601–2604


Jagadeeshwar R. Rao, Ashok K. Jha, Ravindra K. Rawal, Ashoke Sharon, Craig W. Day, Dale L. Barnard, Donald F. Smee, Chung K. Chu*



Enantiomerically pure cyclopentyl cytosine [(–)-carbodine] exhibited potent antiviral activity against H5N1 (avian) and novel H1N1 (swine) flu.

(S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl)propanoic acid compounds: Synthesis and biological evaluation of dual PPAR α/γ agonists pp 2605–2608


Xinbo Zhou, Wei Chen, Cheng Xu, Shiyong Fan, Yunde Xie, Wu Zhong, Lili Wang, Song Li*



A series of novel, potent PPAR α/γ dual agonists were synthesized and appraised. Compound **2b** was chosen for further in vivo evaluation in the *db/db* mice, rosiglitazone were used for comparison.


Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors pp 2609–2613

Carole Pissot-Soldermann*, Marc Gerspacher, Pascal Furet, Christoph Gaul, Philipp Holzer, Clive McCarthy, Thomas Radimerski, Catherine H. Regnier, Fabienne Baffert, Peter Drueckes, Gisele A. Tavares, Eric Vangrevelinghe, Francesca Blasco, Giorgio Ottaviani, Flavio Ossola, Julien Scesa, Janitha Reetz




Design, synthesis and in vitro/in vivo evaluation of orally bioavailable prodrugs of a catechol-O-methyltransferase inhibitor pp 2614–2616

Jarkko Rautio*, Jukka Leppänen, Marko Lehtonen, Krista Laine, Mikko Koskinen, Jarmo Pystynen, Jouko Savolainen, Mikko Sairanen



The introduction of P4 substituted 1-methylcyclohexyl groups into Boceprevir®: A change in direction in the search for a second generation HCV NS3 protease inhibitor pp 2617–2621


Frank Bennett*, Yuhua Huang, Siska Hendrata, Raymond Lovey, Stephane L. Bogen, Weidong Pan, Zhuyan Guo, Andrew Prongay, Kevin X. Chen, Ashok Arasappan, Srikanth Venkatraman, Francisco Velazquez, Latha Nair, Mousumi Sannigrahi, Xiao Tong, John Pichardo, Kuo-Chi Cheng, Viyyoor M. Girijavallabhan, Anil K. Saksena, F. George Njoroge



52 K_i* = 3 nM; EC₉₀ = 80 nM
Monkey AUC=3.2uM.h (3mpk)

4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: First boronic acid-derived beta-lactamase inhibitor with class A, C, and D activity pp 2622–2624


Qiang Tan*, Aimie M. Ogawa, Ronald E. Painter, Young-Whan Park, Katherine Young, Frank P. DiNinno



4,7-Dichloro-1-benzothien-2-yl sulfonylaminomethyl boronic acid (DSABA) is reported as the first boronic acid-based class D beta-lactamase inhibitor, also with class A and C activity.

Synthesis and bioluminescence-inducing properties of autoinducer (S)-4,5-dihydroxypentane-2,3-dione and its enantiomer pp 2625–2628

Manikandan Kadirvel, William T. Stimpson, Souad Moumene-Afifi, Biljana Arsic, Nicola Glynn, Nigel Halliday, Paul Williams, Peter Gilbert, Andrew J. McBain, Sally Freeman, John M. Gardiner*




Synthesis of both enantiomers of autoinducer DPD (shown (S), R = H) along with their ester bioprecursors (R = Bz, Ac) & biological assays.



Selectivity profiling of novel indene H₁-antihistamines for the treatment of insomnia pp 2629–2633

Bin-Feng Li, Wilna J. Moree*, Jinghua Yu, Timothy Coon, Said Zamani-Kord, Siobhan Malany, Kayvon Jalali, Jianyun Wen, Hua Wang, Chun Yang, Samuel R. J. Hoare, Robert E. Petroski, Ajay Madan, Paul D. Crowe, Graham Beaton*




Structure–activity relationships were conducted around a lead H₁-antihistamine **2**, to identify selective analogs with the potential for reduced biotransformation through the CYP2D6 pathway. A number of candidate compounds were identified from the general structure **4** using the appropriate combination of electron rich heterocycles, the presence of a chiral center and 6-substitution in the indene core.



Identification of SD-0006, a potent diaryl pyrazole inhibitor of p38 MAP kinase pp 2634–2638

John K. Walker*, Shaun R. Selness, Rajesh V. Devraj, Michael E. Hepperle, Win Naing, Huey Shieh, Ravi Kurambail, Syaulan Yang, Daniel L. Flynn, Alan G. Benson, Dean M. Messing, Tom Dice, Tina Kim, R. J. Lindmark, Joseph B. Monahan, Joseph Portanova




Starting from the novel screening lead, SC-102, synthesis and structure activity relationships are provided highlighting the progression to and identification of the potent p38 MAP kinase inhibitor SD-0006.

Discovery of novel *N*-acylsulfonamide analogs as potent and selective EP3 receptor antagonists

pp 2639–2643

Masaki Asada*, Tetsuo Obitsu, Atsushi Kinoshita, Yoshihiko Nakai, Toshihiko Nagase, Isamu Sugimoto, Motoyuki Tanaka, Hiroya Takizawa, Ken Yoshikawa, Kazutoyo Sato, Masami Narita, Shuichi Ohuchida, Hisao Nakai, Masaaki Toda




Identification of novel *N*-acyl 3,4-difluorobenzenesulfonamide analogs as potent and selective EP3 receptor antagonists and their in vivo efficacy with respect to the PGE₂-induced uterine contraction in pregnant rats are reported.

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors

pp 2644–2647

Arie Zask*, Jeroen C. Verheijen, David J. Richard, Joshua Kaplan, Kevin Curran, Lourdes Toral-Barza, Judy Lucas, Irwin Hollander, Ker Yu




Incorporation of bridged morpholines in monocyclic triazine PI3K/mTOR inhibitors gave compounds with increased mTOR selectivity relative to the corresponding morpholine analogs leading to compounds which suppressed mTOR biomarkers in vivo and possessed excellent efficacy in a murine xenograft model.

2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability

pp 2648–2653

Jeroen C. Verheijen*, David J. Richard, Kevin Curran, Joshua Kaplan, Ker Yu, Arie Zask




Isosteric replacement of one of the 3,5-ethylene-bridged morpholines in triazine mTOR inhibitors led to significant improvements in human microsomal stability, resulting in a compound that selectively suppressed mTOR biomarkers in vivo and possessed excellent efficacy in a murine xenograft model.

Triazines incorporating (*R*)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3K α

pp 2654–2657

David J. Richard*, Jeroen C. Verheijen, Ker Yu, Arie Zask




Potent inhibitors of the mammalian target of rapamycin (mTOR) which contain the triazine scaffold and the (*R*)-3-methyl morpholine moiety have been identified. Such compounds also displayed excellent cellular activity and good selectivity over the related lipid kinase PI3K α .

1,7-Disubstituted oxyindoles are potent and selective EP₃ receptor antagonists


Nian Zhou, Alexandre M. Polozov, Matthew O'Connell, James Burgeson, Peng Yu, Wayne Zeller, Jun Zhang, Emmanuel Onua, Jose Ramirez, Gudrun A. Palsdottir, Gudrun V. Halldorsdottir, Thorkell Andresson, Alex S. Kiselyov, Mark Gurney, Jasbir Singh*

pp 2658–2664

**Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder**

Shoukath M. Ali, Ateeq Ahmad, Syed Shahabuddin, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad*

pp 2665–2667




A novel synthesis of endoxifen and its PKC inhibitory activity is reported.

A new cytotoxic tambjamine alkaloid from the Azorean nudibranch *Tambja ceutae*


Marianna Carbone, Carlo Irace, Francesca Costagliola, Francesco Castelluccio, Guido Villani, Gonalo Calado, Vinicius Padula, Guido Cimino, J. Lucas Cervera, Rita Santamaria, Margherita Gavagnin*

pp 2668–2670

**Synthesis and antibacterial activity of new 9-O-arylpropenyloxime ketolides**

Ghilsoo Nam*, Yang Soo Kim, Kyung Il Choi

pp 2671–2674


**9-O-Arylpropenyloxime ketolides**

New 9-O-arylpropenyloxime ketolides were synthesized and evaluated their antibacterial activities against clinically isolated gram-positive strains. The SAR is discussed.

Enhanced Nrf2-dependent induction of glutathione in mouse embryonic fibroblasts by isoselenocyanate analog of sulforaphane

pp 2675–2679

Sans W. Emmert, Dhimant Desai, Shantu Amin, John P. Richie Jr.*




SFN-isoSe, an isosteric selenium analog of naturally occurring sulforaphane (SFN), is a potent inducer of the Nrf2/ARE pathway and may represent a more effective chemoprotective agent in vivo.

Conformationally-restricted amino acid analogues bearing a distal sulfonic acid show selective inhibition of system x_c⁻ over the vesicular glutamate transporter

pp 2680–2683

Jean-Louis G. Etoga, S. Kaleem Ahmed, Sarjubhai Patel, Richard J. Bridges, Charles M. Thompson*



block approx. 75% uptake of system x_c⁻

OTHER CONTENTS**Corrigenda**

pp 2684–2685

*Corresponding author

①⁺ Supplementary data available via ScienceDirect**COVER**

Overlay of high resolution co-crystal structures of *R*-22-ADP (cyan) and 1-ADP (green) bound in an allosteric binding site of the mitotic kinesin KSP. [Roecker, A. J.; Coleman, P. J.; Mercer, S. P.; Schreier, J. D.; Buser, C. A.; Walsh, E. S.; Hamilton, K.; Lobell, R. B.; Tao, W.; Diehl, R. E.; South, V. J.; Davide, J. P.; Kohl, N. E.; Yan, Y.; Kuo, L. C.; Li, C.; Fernandez-Metzler, C.; Mahan, E. A.; Prueksaritanont, T.; Hartman, G. D. *Bioorg. Med. Chem. Lett.* **2007**, 17, 5677.]

Indexed/Abstracted in: Beilstein, Biochemistry & Biophysics Citation Index, CANCERLIT, Chemical Abstracts, Chemistry Citation Index, Current Awareness in Biological Sciences/BIOBASE, Current Contents: Life Sciences, EMBASE/Excerpta Medica, MEDLINE, PASCAL, Research Alert, Science Citation Index, SciSearch, TOXFILE. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®




ELSEVIER

ISSN 0960-894X



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

Shoukath M. Ali, Ateeq Ahmad, Syed Shahabuddin, Moghis U. Ahmad, Saifuddin Sheikh, Imran Ahmad*

Jina Pharmaceuticals, Inc. 28100 N. Ashley Circle, Suite 103, Libertyville, IL 60048, USA

ARTICLE INFO

Article history:

Received 12 December 2009

Accepted 5 February 2010

Available online 23 February 2010

Keywords:

Endoxifen

PKC

Bipolar disorder

Chemical synthesis

ABSTRACT

Protein kinase C (PKC) plays a major role in regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. Tamoxifen, a widely used breast cancer drug is known to inhibit PKC and demonstrate antimanic properties in human. We describe herein the synthesis of endoxifen, a tamoxifen active metabolite and compared its PKC inhibitory activity with that of tamoxifen. Endoxifen exhibited fourfold higher potency compared to tamoxifen.

© 2010 Elsevier Ltd. All rights reserved.

Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability, that affects adult population.¹ Until recently, not much was known about the molecular and cellular mechanisms of BPD. Recent data suggests that mania is associated with overactive protein kinase C (PKC) intracellular signaling which plays a major role in regulation of both pre and postsynaptic neurotransmission.² Interestingly, the current first line therapy of mania, lithium and valproate indirectly inhibit PKC.³ In addition, recent preclinical and clinical studies with the relatively selective PKC inhibitor Z-tamoxifen add support to the relevance of the PKC target in BPD. Animal studies demonstrate that tamoxifen significantly reduced manic behavior in rodents.⁴ Preliminary investigations of PKC inhibitor tamoxifen in the treatment of acute mania showed anti-manic effects compared to placebo.⁵ Recently, two groups confirmed antimanic properties of tamoxifen in double-blind, placebo controlled clinical studies.⁶ Thus, a growing body of work in both preclinical and clinical indicates that PKC signalling may play an important factor in the pathophysiology and treatment of BPD. The development of CNS-penetrant PKC inhibitors such as tamoxifen may have considerable benefit for this devastating illness.⁷ However, there is a large inter-individual and ethnic variability in tamoxifen bioavailability and function due to CYP2D6 genetic polymorphism which extensively metabolizes tamoxifen into active metabolites, 4-hydroxy tamoxifen and 4-hydroxy-N-desmethyl tamoxifen (endoxifen).⁸ Alternative PKC inhibitors that are independent of CYP2D6 action such as endoxifen may provide better opportunity for the treat-

ment of BPD and other diseases. Here we have synthesized endoxifen (Fig. 1) and showed its PKC inhibitory activity in vitro for the first time. We have also compared its PKC activity with known PKC inhibitor tamoxifen.

Previously reported endoxifen synthesis involved demethylation of 4-hydroxytamoxifen.⁹ However, there are no reports for its synthesis starting from commercially available starting materials. Here, we report the synthesis of endoxifen starting from commercially available 4-bromophenol, α -phenyl butyric acid and 2-chloroethoxybenzene. The synthetic scheme is depicted in Scheme 1. 1-[4-(2-Chloroethoxy)phenyl]-2-phenyl-butan-1-one **3** was synthesized by refluxing solution of 2-phenylbutyric acid **2** and thionyl chloride in 1,2-dichloroethane (EDC) for an hour before it was cooled to room temperature and added drop wise to a stirring solution of 2-chloroethoxybenzene **1** and anhydrous aluminum chloride in EDC at 0 °C. After the completion of reaction the workup was done by pouring the reaction solution in HCl/H₂O solution (1:1) and extracted with EDC. The crude product was purified by flash chromatography (hexane/ethyl acetate) yielding **3** in 88% yield. Alternatively, **3** was also synthesized in 96% yield by





Figure 1. Structure of endoxifen.

* Corresponding author. Tel.: +1 847 573 0771.

E-mail address: imran@jinapharma.com (I. Ahmad).



Scheme 1. Reagents and conditions: (a) method: (i) **2**, SOCl_2 , EDC; **3**, AlCl_3 , EDC; (b) method: (ii) TFAA, rt; (c) concd H_2SO_4 , rt; (d) (i) **6**, Mg, THF, reflux \rightarrow rt; (ii) add **3** in THF, reflux; (e) concd HCl, MeOH, reflux; (f) methylamine, 2-propanol, reflux.

mixing **1**, **2**, and trifluoroacetic anhydride (TFAA) and stirring for 10 h. The reaction solution was neutralized with saturated sodium bicarbonate solution before it was extracted with ethyl acetate and concentrated. The crude product after crystallization in hexane at 0°C provided **3** in 96% yield. The tetrahydropyran (THP) protecting group was introduced into 4-bromophenol **4** by stirring with 3 M equiv of 3,4-dihydro-2H-pyran **5** and catalytic amount of concentrated sulfuric acid at 0°C under nitrogen for 30 min. The reaction solution was diluted with hexane–water. After workup, the product was isolated in 91% yield by crystallization in small amount of cold hexane. Compounds **3** and **6** were reacted under Grignard's reaction conditions (Mg/THF) to provide an intermediate **7** which was heated under acidic condition (HCl and methanol) to undergo simultaneously dehydration and deprotection reaction. After conventional workup, the crude product was purified on silica gel column and eluted with dichloromethane–hexane mixture (1:1) to afford 1-[4-(2-chloroethoxy)phenyl]-(4-hydroxyphenyl)-2-phenyl but-1-ene **8** as *E*- and *Z*-geometric isomers in 86.5% yield. Compound **8** was then transformed into compound **9** by treatment with 40% methylamine (aqueous) in isopropyl alcohol and refluxed for 48 h. The solvent was removed and the residue was extracted with ethyl acetate and washed with 5% aq sodium bicarbonate solution followed by water and brine solution.

After drying over anhydrous sodium sulfate, the organic extract was concentrated in vacuo and subsequently triturated with ethyl acetate/hexane (1:1) to provide a mixture (*E*:*Z*, 5.8:4.2, HPLC) of geometric *E*- and *Z*-isomers of endoxifen in 52% yield. *Z*-Endoxifen was isolated in pure form by fractional crystallization in benzene. The product and the intermediates were characterized¹⁰ by ^1H NMR, ^{13}C NMR, high resolution Mass spectrometry. The *Z*-configuration was assigned based on the characteristic chemical shift^{9b,11} of OCH_2 in ^1H NMR. In all tamoxifen derivatives studies, the *Z*-isomers (*trans*), the OCH_2 protons of the side chain have a chemical shift (δ) less than 4.00 ppm owing to the through-space shielding influence of the vicinal 2-phenyl substituents. Based on this, the

isomer having the triplet at δ 3.86 was assigned as *Z*-isomer and the isomer with δ 4.03 was identified as *E*-isomer.

Effect of synthesized endoxifen on PKC activity was evaluated in vitro and compared with that of tamoxifen using a PKC kinase activity ELISA assay kit (Assay Designs, Ann Arbor, MI) which contained a PKC Substrate Microtiter Plate, Active PKC, ATP, Phospho-specific Substrate Antibody, Anti-Rabbit IgG-HRP conjugate, TMB substrate, Stop solution, Wash and Dilution Buffer. The assay was carried out according to manufacturer's instructions. Briefly, 50 μl of a reaction mix containing Kinase Assay Dilution Buffer, 0.025, 0.05, 0.1, or 0.2 mM endoxifen and 10 ng PKC was added to each well of a presoaked PKC Substrate Microtiter Plate. To compare PKC inhibition activity with tamoxifen, 50 μl of the Dilution Buffer reaction mix containing 0.025, 0.05, 0.1, or 0.2 mM tamoxifen (Toronto Research Chemicals, North York, ON, Canada) and 10 ng PKC was added to another set of wells. Fifty microliter of Kinase Assay Dilution Buffer alone or with 10 ng PKC was used as negative and positive controls, respectively. The reaction was initiated by adding 10 μl of diluted ATP to each well. Following incubation at 30°C for up to 90 min, the reaction was stopped by emptying contents of the plate. Forty microliters of Phosphospecific Substrate Antibody was added to each well followed by 60 min incubation at room temperature. All wells were washed four times with Wash Buffer and 40 μl of diluted Anti-Rabbit IgG: HRP Conjugate was added. After 30 min incubation at room temperature, wells were again washed and 60 μl of TMB Substrate was added. Following further incubation at room temperature for 30 min, 20 μl of Stop Solution was added and absorbance was read at 450 nm in a microplate reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA). The results were analyzed using SoftMax[®] Pro 5 software.

Endoxifen inhibited PKC activity in concentration dependent manner. The percentage PKC inhibition ranged between 12% and 78% with endoxifen concentration between 0.025 and 0.2 mM, respectively. In comparison, tamoxifen was found less potent PKC inhibitor at 0.1 and 0.2 mM resulting 14% and 25% PKC inhibition, respectively; lower concentrations of tamoxifen (0.025 and 0.05 mM) showed negligible PKC inhibition. Figure 2 shows endoxifen and tamoxifen induced PKC inhibition at 0.2 mM. The study demonstrated that endoxifen is about fourfold more potent PKC inhibitor than tamoxifen, and suggests its pivotal role in BPD.

In summary, we have synthesized endoxifen that inhibited PKC significantly in comparison with tamoxifen. Preclinical and clinical evidence demonstrate that PKC is an important target—perhaps the first mechanistically distinct drug target for BPD and tamoxifen is a relatively selective PKC inhibitor. This is the first report demonstrating endoxifen to be potentially a superior candidate for BPD treatment especially for those with defects in activating enzymes




Figure 2. Percentage inhibition of PKC activity by 0.2 mM endoxifen and tamoxifen in vitro.

for tamoxifen metabolism. Repeated daily oral administration of endoxifen up to 4 mg/kg and 8 mg/kg body weight in rats and mice, respectively, for 28 days showed no signs of toxicity (unpublished observation). Efficacy studies with endoxifen will be the subject of further investigation.

References and notes

- (a) Goodwin, F. K.; Jamison, K. R. *Manic-Depressive Illness*; Oxford University Press: New York, 1990; (b) Weissman, M. M.; Leaf, P. J.; Tishler, G. L.; Blazer, D. G.; Karno, M.; Bruce, M. L.; Florio, L. P. *Psychol. Med.* **1988**, *18*, 141.
- (a) Wang, H. Y.; Friedman, E. *Biol. Psychiatry* **1996**, *40*, 568; (b) Manji, H. K.; Lenox, R. H. *Biol. Psychiatry* **1999**, *46*, 1328.
- Friedman, E.; Hoau Yan, W.; Levinson, D.; Connell, T. A.; Singh, H. *Biol. Psychiatry* **1993**, *33*, 520.
- (a) Einat, H.; Manji, H. K. *Biol. Psychiatry* **2006**, *59*, 1160; (b) Narita, M.; Aoki, T.; Ozaki, S.; Yajima, Y.; Suzuki, T. *Neuroscience* **2001**, *103*, 309.
- (a) Kulkarni, J.; Garland, K. A.; Scaffidi, A.; Headey, B.; Anderson, R.; de Castella, A.; Fitzgerald, P.; Davis, S. R. *Psychoneuroendocrinology* **2006**, *31*, 543; (b) Bechuk, J. M.; Arfken, C. L.; Dolan-Manji, S.; Murphy, J.; Hasanat, K.; Manji, H. K. *Arch. Gen. Psychiatry* **2000**, *57*, 95.
- (a) Yildiz, A.; Guleryuz, S.; Ankerst, D. P.; Ongur, D.; Renshaw, P. F. *Arch. Gen. Psychiatry* **2008**, *65*, 255; (b) Zarate, C. A., Jr.; Singh, J. B.; Carlson, P. J.; Quiroz, J.; Jolkovsky, L.; Luckenbaugh, D. A.; Manji, H. K. *Bipolar Disord.* **2007**, *9*, 561.
- DiazGranados, N.; Zarate, C. A., Jr. *Curr. Psychiatry Rep.* **2008**, *10*, 510.
- Information P. NOLVADEX® Product Monograph (Tamoxifen citrate). Copyright, AstraZeneca Canada, Inc. 2000.
- (a) Stearns, V.; Johnson, M. D.; Rae, J. M.; Morocho, A.; Novielli, A.; Bhargava, P.; Hayes, D. F.; Desta, Z.; Flockhart, D. A. *J. Natl. Cancer Inst.* **2003**, *95*, 1758; (b) Sun, D.; Sharma, A. K.; Dellinger, R. W.; Blevins-Primeau, A. S.; Balliet, R. M.; Chen, G.; Boyiri, T.; Amin, S.; Lazarus, P. *Drug Metab. Dispos.* **2007**, *35*, 2006.
- Compound 6**: mp 56–57 °C; ¹H NMR (400 MHz, CDCl₃): δ 1.68 (m, 3H), 1.83 (m, 2H), 1.98 (m, 1H), 3.57 (m, 1H), 3.85 (m, 1H), 5.36 (t, J = 3.2 Hz, 1H), 6.93 (AB, J = 8.79, J = 2.14, 2H), 7.35 (AB, J = 8.79, J = 2.14 Hz, 2H), ¹³C NMR (100 MHz, CDCl₃): δ 18.6, 25.1, 30.2, 61.9, 96.5, 113.8, 118.3, 132.2, 156.2; HRMS (ESI), expected 278.991, observed 278.9984 (M+Na⁺). **Compound 3**: mp 68–70 °C; ¹H NMR (400 MHz, CDCl₃): δ 0.89 (t, J = 7.5 Hz, 3H), 1.85 (m, 1H), 2.18 (m, 1H), 3.78 (t, J = 5.9 Hz, 2H), 4.22 (t, J = 5.9 Hz, 2H), 4.38 (t, J = 7.26 Hz, 1H), 6.86 (AB, J = 9 Hz, J = 2.14 Hz, 2H), 7.18 (m, 1H), 7.28 (m, 4H), 7.96 (AB, J = 8.78 Hz, J = 1.93 Hz, 2H), ¹³C NMR (100 MHz, CDCl₃): δ 12.3, 27.1, 41.5, 55.1, 67.9, 114.2, 126.8, 128.2, 128.8, 130.6, 130.9, 139.9, 161.7, 198.5. HRMS (ESI), expected 325.0966, observed 325.0976 (M+Na⁺). **Compound 9 (Z-endoxifen)**: mp 139–143 °C; ¹H NMR (400 MHz, DMSO-d₆): δ 0.85 (t, J = 7.24 Hz, 3H), 2.29 (s, 3H), 2.42 (q, J = 7.2 Hz, 2H), 2.74 (t, J = 5.59 Hz, 3H), 3.86 (t, J = 5.56 Hz, 2H), 6.58 (d, J = 8.78 Hz, 2H), 6.71 (d, J = 8.56 Hz, 2H), 6.75 (d, J = 8.68 Hz, 2H), 6.98 (d, J = 8.2 Hz, 2H), 7.08–7.13 (m, 3H), 7.15–7.19 (m, 2H), 9.38 (br, 1H); HRMS (ESI), expected 374.2115, observed 374.2116 (M+H⁺).
- McCague, R.; Leclercq, G.; Legros, N.; Goodman, J.; Blackburn, G. M.; Jarman, M.; Foster, A. B. *J. Med. Chem.* **1989**, *32*, 2527.